News

SinoVeda Canada has signed an exclusive license agreement with Exzell Pharma to commercialize Effecti-Cal in Canada, the US, Australia and New Zealand. The agreement includes upfront and milestone

Earlier in January, the company entered into a world-wide collaboration with UCB to develop and commercialize NPT200-11 in all indications. So far, the company has secured $20.5m of

The trial met its primary endpoint, showing that venetoclax monotherapy resulted in a clinically meaningful reduction in the number of cancer cells in a pre-defined proportion of people

Vonapanitase is an investigational drug that may prolong the patency and reduce the failure of hemodialysis vascular access in patients with CKD. The new trial complements the first

The earlier collaboration between the two firms focused on the discovery of new treatments for neuropsychiatric disorders, while the new three-year deal will focus on investigating new medicines

HD is caused by the progressive breakdown of nerve cells in the brain that affects about five to seven people per 100,000 in western countries, according to the

G1T28 is an intravenous (IV) therapy being studied as a bone marrow and immune system chemoprotectant in patients with SCLC who are receiving chemotherapy. The two Phase 1b/2a

Centyrins are a class of Janssen proprietary alternative scaffold molecules that can be engineered to bind to target proteins with an interface of similar size to those used

Brintellix was discovered by Lundbeck researchers and the clinical trial program in the US was conducted jointly by the two firms, while Takeda holds the NDA for the